抗逆转录病毒治疗中断后HIV反弹的病毒学与免疫学危险因素
研究分析了苏黎世HIV原发感染队列(ZPHI,n=73)和ACTG A5345研究(n=44)参与者治疗中断前的外周血单个核细胞,检测细胞相关HIV RNA、总HIV DNA和原病毒多样性,并用流式细胞术进行免疫表型分析。Cox比例风险模型和自适应LASSO惩罚Cox模型识别至反弹时间(HIV RNA>1000拷贝/mL)的危险因素。结果显示晚期启动ART、治疗前高血浆HIV RNA、高总HIV DNA、治疗中断时高细胞HIV转录、高原病毒多样性(仅男性和ZPHI队列)、较少CD4+ T细胞及更多效应/终末分化/活化/耗竭T细胞与更高反弹风险相关;慢性HIV期治疗者未见显著免疫学危险因素。
要点
- 晚期启动ART者反弹风险高于早期启动者(至反弹时间更短)。
- 治疗中断时总HIV DNA和终末分化CD8+ T细胞是联合队列中最相关的反弹危险因素。
- 早期治疗者中较少CD4+ T细胞及更多活化/耗竭T细胞与更高反弹风险相关。
核心结论
- 研究结果强调早期启动ART的重要性,并提示基于病毒学、免疫学和人口学因素的个体化干预可能有助于实现持续病毒抑制。
研究设计与样本
- 分析苏黎世HIV原发感染队列(ZPHI,n=73)和ACTG研究A5345(n=44)参与者在ART中断前的外周血单个核细胞。
- 检测细胞相关HIV RNA、总HIV DNA和原病毒多样性(env基因),并用流式细胞术进行免疫表型分析。
- 采用Cox比例风险模型和带自适应LASSO惩罚的惩罚Cox比例风险模型识别至反弹时间(HIV RNA>1000拷贝/mL)的危险因素。
主要发现
- 与早期启动ART相比,晚期启动ART与更高的反弹风险相关(至反弹时间更短)。
- ART前血浆HIV RNA更高、总HIV DNA更高以及ART中断时细胞HIV转录增加与更高的反弹风险相关。
- 原病毒多样性更高与更高的反弹风险相关,但仅在男性参与者及ZPHI队列入组者中。
- ART中断时CD4+ T细胞较少、效应和终末分化T细胞比例更高、活化和耗竭T细胞更多与更高的反弹风险相关,主要在早期治疗参与者中。
- 在慢性HIV期治疗的参与者中未发现显著的免疫学危险因素;在联合队列中,多变量分析变量选择显示总HIV DNA和终末分化CD8+ T细胞似乎是至反弹时间最相关的危险因素。
临床怎么用
- 作者认为这些发现强调早期启动ART的重要性,并提示基于病毒学、免疫学和人口学因素的个体化干预可能有助于实现持续病毒抑制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Identifying risk factors for human immunodeficiency virus (HIV) rebound after treatment interruption is crucial for designing effective remission strategies. METHODS: Peripheral blood mononuclear cells from participants in the Zurich HIV Primary Infection Cohort (ZPHI, n = 73) and ACTG study A5345 (n = 44) were analyzed before antiretroviral therapy (ART) interruption. We measured cell-associated HIV RNA, total HIV DNA, and proviral diversity (env gene). Immune phenotyping was conducted by flow cytometry. Cox proportional hazards (PH) models and penalized Cox PH models with an adaptive LASSO penalty identified risk factors for time to rebound (HIV RNA >1000 copies/mL). RESULTS: Late ART initiation was associated with higher rebound risk (shorter time to rebound) as compared to early ART. Higher pre-ART HIV RNA in plasma, total HIV DNA, and increased cellular HIV transcription at the time of ART interruption were associated with higher rebound risk. Higher proviral diversity was associated with higher rebound risk but only among male participants and those enrolled in the ZPHI cohort. Fewer CD4+ T cells at ART interruption, higher proportions of effector and terminally differentiated T cells, and more activated and exhausted T cells were associated with higher rebound risk, primarily in early-treated participants. No significant immunological risk factors were found in participants treated during chronic HIV. In the combined cohort, total HIV DNA and terminally differentiated CD8+ T cells appeared to be the most relevant risk factors for time to rebound, as indicated by variable selection in multivariable analysis. CONCLUSIONS: These findings underscore the importance of early ART initiation and suggest that tailored interventions based on virologic, immunologic, and demographic factors may help achieve sustained viral suppression. Clinical Trials Registration. NCT00537966 and NCT03001128.
引用
- Gianella S, Yu T, Wang R, et al. Viral and Immune Risk Factors of HIV Rebound After Interruption of Antiretroviral Therapy. J Infect Dis. 2025. PMID: 39661441. doi:10.1093/infdis/jiae585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。